News coverage about PDL BioPharma (NASDAQ:PDLI) has been trending somewhat positive on Thursday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PDL BioPharma earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.7720064663391 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Pluristem’s Ischemia Candidate Gets Fast Track Designation (finance.yahoo.com)
- PDL BioPharma Updates Presentation Time for Cantor Fitzgerald Conference (finance.yahoo.com)
- Financial Contrast: PDL BioPharma (PDLI) vs. Charles River Laboratories International (CRL) (americanbankingnews.com)
- Pdl Biopharma Inc (PDLI): Stock Overview – ExpertGazette (expertgazette.com)
- 3 Pharma/Biotech Sector Bargains for a Healthy Portfolio (finance.yahoo.com)
Several equities analysts have weighed in on the stock. ValuEngine lowered shares of PDL BioPharma from a “buy” rating to a “hold” rating in a research note on Wednesday, September 6th. Zacks Investment Research upgraded shares of PDL BioPharma from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Wednesday, August 16th. BidaskClub upgraded shares of PDL BioPharma from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $4.00 target price on shares of PDL BioPharma in a report on Thursday, August 10th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $3.50.
Shares of PDL BioPharma (PDLI) opened at 3.31 on Thursday. The company has a 50-day moving average of $2.87 and a 200-day moving average of $2.44. The company has a market cap of $510.00 million, a PE ratio of 7.61 and a beta of 0.49. PDL BioPharma has a 1-year low of $1.93 and a 1-year high of $3.77.
PDL BioPharma (NASDAQ:PDLI) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.17. PDL BioPharma had a return on equity of 9.07% and a net margin of 23.03%. The firm had revenue of $143.80 million during the quarter, compared to analyst estimates of $56.30 million. During the same quarter in the prior year, the firm posted $0.09 earnings per share. The business’s quarterly revenue was up 584.8% compared to the same quarter last year. Equities analysts forecast that PDL BioPharma will post $0.61 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/09/21/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-pdl-biopharma-pdli-share-price.html.
PDL BioPharma Company Profile
PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.
Receive News & Ratings for PDL BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.